10-K: ProKidney Corp. Reports Continued Losses in 2024 Amid Phase 3 Clinical Trial Progress

ProKidney Corp.'s 2024 10-K filing reveals ongoing net losses as the company advances its rilparencel clinical development program for chronic kidney disease.

Summary

• ProKidney Corp., a clinical-stage biotechnology company, filed its 10-K report for the fiscal year ended December 31, 2024.
• The company is focused on developing rilparencel, a cell therapy for chronic kidney disease (CKD).
• ProKidney reported net losses of $163.3 million in 2024, $135.4 million in 2023 and $148.1 million in 2022.
• As of December 31, 2024, the company had approximately $358.3 million in cash, cash equivalents and short-term investments.
• ProKidney believes these funds will be sufficient to fund operations into mid-2027.
• The company is conducting a Phase 3 clinical study (PROACT 1) and an ongoing Phase 2 clinical study for rilparencel in subjects with moderate to severe CKD and diabetes.
• Rilparencel has received regenerative medicine advanced therapy (RMAT) designation from the FDA.
• The company discontinued REGEN-016 (PROACT 2) and the FDA confirmed that PROACT 1 could be sufficient to support a potential Biologics License Application (BLA) submission.
• ProKidney is exploring an accelerated approval pathway with eGFR slope as a surrogate endpoint.
• The company resumed manufacturing for U.S. and non-European clinical study sites in June 2024, and in July 2024, received the Qualified Person (QP) Declaration of Equivalence to European Union Good Manufacturing Practice (GMP) standards.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's progress in clinical trials and manufacturing, the company continues to experience significant losses and faces numerous risks and uncertainties.

Positives

• The FDA has confirmed that the Phase 3 PROACT 1 trial could be sufficient for a BLA submission.
• Rilparencel has received RMAT designation, potentially expediting the approval process.
• The company has sufficient cash to fund operations into mid-2027.
• Manufacturing has resumed for U.S. and non-European clinical study sites.
• The company received the Qualified Person (QP) Declaration of Equivalence to European Union Good Manufacturing Practice (GMP) standards.

Negatives

• The company has incurred significant net losses since inception and expects to continue to do so for the foreseeable future.
• The company has no products approved for commercial sale and has not generated any revenue.
• The company is dependent on the success of its lead product candidate, rilparencel.
• Clinical trials may be delayed due to various factors, including patient enrollment and regulatory requirements.
• The company faces significant competition in the biologics market and in the area of treatment of kidney disease.

Risks

• The company's ability to achieve or maintain profitability is uncertain.
• Clinical trials may fail or be delayed, preventing regulatory approval.
• The company may not be able to manufacture rilparencel or other product candidates to meet development or commercial needs.
• The company's product candidates may not be accepted in the market, even if approved.
• The company relies on third parties for various aspects of its business, including clinical trials and manufacturing.
• The company is subject to extensive legal and regulatory compliance matters.
• The company's intellectual property may not be adequately protected.
• The company may face difficulties in managing its business and operations, including attracting and retaining key personnel.
• The company's organizational structure and tax obligations could create financial challenges.

Future Outlook

ProKidney expects its existing cash, cash equivalents and marketable securities to fund its operating expenses and capital expenditure requirements into mid-2027 and plans to continue clinical development of rilparencel and explore additional product candidates.

Industry Context

The biotechnology and pharmaceutical industries are characterized by rapid technological advancement, significant competition, and an emphasis on intellectual property. ProKidney faces competition from major and specialty pharmaceutical and biotechnology companies, including developers of SGLT2 inhibitors, antifibrosis medications, and other cell-based therapies.

Comparison to Industry Standards

• The document mentions competition from developers of SGLT2 inhibitors like canagliflozin (Invokana by Janssen), dapagliflozin (Farxiga/Forxiga by AstraZeneca/Bristol-Myers Squibb), and empagliflozin (Jardiance by Boehringer Ingelheim/Eli Lilly).
• It also notes competition from MRAs like finerenone (Kerendia by Bayer AG).
• The document acknowledges the increasing use of GLP-1 agonists like semaglutide (Ozempic/Rybelsus/Wegovy by Novo Nordisk) and tirzepatide (Mounjaro by Eli Lilly), which have shown to reduce mortality in patients with advanced-stage CKD and ESRD.
• The document mentions cell-based clinical trials by other companies are underway globally with umbilical, adipose and bone marrow derived mesenchymal stem cells for CKD.
• Early-phase human induced pluripotent stem cell therapies for kidney diseases are ongoing in Japan.

Related Party Transactions

• The company is party to a tax receivable agreement with a related party which provides for the payment by the Company to holders of PKLP prior to the Closing (Closing ProKidney Unitholders) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions.
• On January 1, 2020, ProKidney-KY (formerly known as inRegen) entered into a consulting services agreement with Nefro Health (Nefro), an Irish partnership controlled and majority-owned by Mr. Pablo Legorreta, a director of the Company, pursuant to which Nefro provides consulting services for the research and development of the Companys product candidates, including the conduct of clinical trials in North America and the European Union, the design and manufacturing of ProKidneys product candidates as well as pre-commercialization activities.
• On January 1, 2020, ProKidney-US (formerly known as Twin City Bio, LLC) entered into a consulting services agreement with Nefro, pursuant to which Nefro provides consulting services for the research and development of the Companys product candidates, including the conduct of clinical trials in North America and the European Union, the design and manufacturing of the Companys product candidates as well as pre-commercialization activities.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings.
• Patients with CKD and diabetes could benefit from the successful development and commercialization of rilparencel.
• Employees face potential job insecurity due to the company's financial challenges and restructuring efforts.
• The company's suppliers and vendors may be affected by changes in its operations and financial condition.

Next Steps

• Continue clinical development of rilparencel through the Phase 3 REGEN-006 trial.
• Engage with the FDA to further define the details supporting the accelerated approval pathway.
• Maintain and refine internal expertise in manufacturing products.
• Investigate additional disease pathways associated with kidney disease and generate product candidates against these targets.

Key Dates